跳至主要内容
临床试验/NCT01170494
NCT01170494已完成不适用

Effect of Vitamin D Oral Supplements on 25 OH Vitamin D Levels: A Randomized Controlled Trial

King Faisal Specialist Hospital & Research Center1 个研究点 分布在 1 个国家目标入组 279 人开始时间: 2013年2月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
279
试验地点
1
主要终点
area under the curve of 25 OH vitamin D level

研究概览

简要总结

Vitamin D deficiency is common world wide. 25 OH vitamin D level is the best indicator of vitamin D status. Vitamin D supplements are available as vitamin D2 or D3, in small daily or large weekly/monthly doses. Controversy continues on the relative potency of vitamin D2 compared to D3 and of daily compared to weekly or monthly doses, in increasing/maintaining total 25 OH vitamin D level.

The investigators plan to conduct a controlled trial to compare the effect of various vitamin D supplements on 25 OH vitamin D levels in healthy adults with starting 25 OH vitamin D level between 20 to 50 nmol/L.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 60 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Healthy adults living in Riyadh area who consume no more than one serving of milk/day, do not take vitamin supplement, habitually have less than 10 hr of sun exposure per week, don't suffer from granulomatous conditions, liver disease, or kidney disease, and don't take anticonvulsants, barbiturates, or steroids.
  • 25 OH vitamin D level between 20 to 50 nmol/L.

排除标准

  • 未提供

研究组 & 干预措施

placebo daily

Placebo Comparator

干预措施: placebo orally everyday (Drug)

D2 25000 IU Q2wk

Active Comparator

干预措施: ergocalciferol 25000 IU oraly every 2 weeks (Drug)

D3 25000 IU Q2wk

Active Comparator

干预措施: Cholecalciferol 25000 IU orally every 2 weeks (Drug)

D2 50000 IU Q4wk

Active Comparator

干预措施: ergocalciferol 50000 IU orally every 4 weeks (Drug)

D3 50000 IU Q4wk

Active Comparator

干预措施: Cholecalciferol 50000 orally every 4 weeks (Drug)

D2 2000 IU daily

Active Comparator

干预措施: ergocalciferol 2000 IU orally, daily (Drug)

D3 2000 IU daily

Active Comparator

干预措施: cholecalciferol 2000 IU orally daily (Drug)

D2 1000 IU + D3 1000 IU daily

Active Comparator

干预措施: ergocal1000 IU & cholecal 1000 IU orally daily (Drug)

结局指标

主要结局

area under the curve of 25 OH vitamin D level

时间窗: 140 days

area under the curve of total 25 OH vitamin D level from day 1 to 140

次要结局

  • Cmax of 25 OH vitamin D(140 days)
  • incidence of hypercalciuria(140 days)
  • Tmax of 25 OH vitamin D level(140 days)
  • area under the curve of vitamin D level(140 days)
  • incidence of hypercalcemia(140 days)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Muhammad Maher Hammami

Chairman, Department of Clinical Studies & Empirical Ethics

King Faisal Specialist Hospital & Research Center

研究点 (1)

Loading locations...

相似试验